Related Experiment Video
Updated: Jun 20, 2026
09:31
Visualization of Amyloid β Deposits in the Human Brain with Matrix-assisted Laser Desorption/Ionization Imaging Mass Spectrometry
Published on: March 7, 2019
Plasma beta-amyloid 1-40 is associated with the diffuse small vessel disease subtype
Meritxell Gomis1, Tomás Sobrino, Angel Ois
1Stroke Unit, Department of Neurociences, Hospital Universitari Germans Trias i Pujol (Badalona), Universitat Autònoma de Barcelona, Barcelona, Spain. mgomis.germanstrias@gencat.cat
Stroke
|August 22, 2009
Summary
Plasma beta-amyloid(1-40) levels are linked to the diffuse subtype of small vessel disease (SVD). This finding suggests a role for beta-amyloid in SVD pathogenesis and endothelial dysfunction.
Area of Science:
- Neurology
- Vascular Biology
- Biochemistry
Background:
- Small vessel disease (SVD) comprises diffuse arteriopathy (diffuse-SVD) and microatheroma (focal-SVD) subtypes.
- Beta-amyloid peptide (Abeta) deposition is implicated in endothelial dysfunction, lacunar infarcts, and leukoaraiosis, but its specific role in SVD subtypes remains unclear.
Purpose of the Study:
- To investigate the differential roles of plasma Abeta levels in patients with acute lacunar stroke, specifically in relation to SVD subtypes.
Main Methods:
- A study involving 149 patients with acute ischemic stroke of SVD etiology and 25 age-matched controls.
- Patients were categorized into focal-SVD (isolated lacunar infarct without leukoaraiosis) and diffuse-SVD (lacunar infarct with leukoaraiosis or multiple lacunar infarcts).
- Plasma Abeta levels, vascular risk factors, and laboratory tests were analyzed.
Main Results:
- Plasma Abeta(1-40) levels were significantly higher in the diffuse-SVD group compared to both focal-SVD and control groups.
- No significant difference in Abeta(1-40) levels was observed between focal-SVD and control subjects.
- Logistic regression identified age, hypertension history, and elevated plasma Abeta(1-40) levels as independent predictors of the diffuse-SVD subtype.
Conclusions:
- Plasma beta-amyloid(1-40) levels are independently associated with the diffuse-SVD subtype.
- These findings support the hypothesis that Abeta(1-40) contributes to endothelial dysfunction in SVD pathogenesis.
Related Concept Videos
01:23Alzheimer Disease ll: Pathophysiology
Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...
01:22Dementia l: Introduction
Dementia is an acquired, progressive syndrome characterized by a decline in multiple cognitive domains severe enough to impair daily functioning and reduce independence. Although memory loss is a central feature, the diagnosis requires additional deficits involving language, executive function, visuospatial skills, judgment, calculation, or abstract reasoning. These cognitive impairments reflect underlying neurodegenerative or vascular processes that gradually disrupt neuronal networks...
01:29Alzheimer Disease l: Introduction
Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
03:03Amyloid Fibrils
Amyloid fibrils are aggregates of misfolded proteins. Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils.
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining, normally used to...
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining, normally used to...
03:03Amyloid Fibrils
Amyloid fibrils are aggregates of misfolded proteins. Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils.
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining, normally used to...
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining, normally used to...
01:26Alzheimer's Disease: Overview
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...